Stem Cell Study for Patients With Leg Ulcer/Gangrene

Chronic critical limb ischemia (CLI) is a progressive disease, which arises as a result of atherosclerosis or vasculitis in leg arteries. Prognosis of chronic CLI is poor, and no effective treatments have been established in patients who are not eligible for the traditional revascularization therapies such as angioplasty and bypass procedures due to the inappropriate anatomy of the leg arteries or frequent reocclusion following revascularization. Therefore, it is necessary to establish novel revascularization treatment to improve prognosis of the no-option patients. We will study the safety and clinical efficiency of vascular regeneration by means of transplantation of autologous peripheral blood endothelial progenitor cells (CD34 positive cells) in patients with chronic CLI who are not eligible for traditional revascularization treatments. The primary endpoint is the primary efficacy score identified by toe brachial blood pressure index (TBPI), absolute claudication distance (ACD) and Wong Baker's pain rating scale, while the secondary endpoints are evaluation of safety, ankle brachial blood pressure index (ABPI), percutaneous tissue oxygen pressure (TcPO2), etc.

Inclusion criteria

• Chronic severe CLI patients fulfilling all the following criteria are considered suitable for inclusion in the study.

• At least 6 months since the onset of CLI (Chronic peripheral artery disease or Buerger disease)
• Patients with luminal stenosis > 50% by leg angiography
• Age is between 20 and 80.
• Patients whose Rutherford's class is II-4, III-5, or III-6（Patients with rest pain or ischemic ulcer/necrosis)
• Patients for whom angioplasty and bypass surgery are not indicated because of anatomical or procedural reasons or frequent reocclusion/ restenosis following the traditional revascularization (No option patients)
• Patients who can give informed consent themselves in writing.

Exclusion criteria

• Any one of the following exclusion criteria is sufficient to disqualify a patient from the study.

• Left ventricular ejection fraction < 25%
• Patients with a history of severe allergic reactions or side effects to G-CSF preparations or apheresis.
• Less than 6 months since last episode of myocardial/cerebral infarction.
• Patients with unstable angina, with a treatment rating of 3 in the Braunwald system, but a severity of III and a clinical rating of B or C.
• Patients with diabetic proliferating retinopathy (new Fukuda classification BI to BV).
• Patients with malignant tumor
• Patients with chronic rheumatoid arthritis.
• Patients with hematological disease (leukemia, myeloproliferative disease, or myelodysplastic syndromes).
• Patients currently suffering from or having a history of interstitial pneumonitis.
• Patients for whom cranial MRA reveals cerebral aneurysm.
• Patients for whom abdominal CT or ultrasonography reveals splenomegaly.
• Patients with cirrhosis of the liver.
• Patients who cannot discontinue Warfarin.
• Leukocytes less than 4,000/µL or exceeding 10,000/µL.
• Platelets less than 100,000/µL.
• Hemoglobin less than 10 g/dL.
• AST (GOT) exceeding 100 IU/L or ALT (GPT) exceeding 100 IU/L.
• Patients with severe neural disorder in their legs.
• Patients with gait disturbance for reasons other than CLI (such as sciatic neuralgia, or vasculitis), making exercise tolerance evaluation on a treadmill with stress ECG difficult.
• Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming pregnant before the end of the study period.
• Any other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.